• Bulletin of the Korean Chemical Society
• /
• 제32권8호
• /
• pp.2700-2704
• /
• 2011

The 1:1 imine intermediate generated by the addition of primary amine to chloroacetone is trapped by N-isocyaniminotriphenylphosphorane in the presence of (E)-cinnamic acids and the corresponding iminophosphorane intermediate was formed. Disubstituted 1,3,4-oxadiazole derivatives are formed via intramolecular aza-Wittig reaction of the iminophosphorane intermediate. The reactions were completed in neutral conditions at room temperature. The disubstituted 1,3,4-oxadiazole derivatives were produced in excellent yields.

• 대한화학회지
• /
• 제54권4호
• /
• pp.414-418
• /
• 2010

Ethyl 1-aminotetrazole-5-carboxylate (1)를 hydrazine hydrate와 반응시켜서 대응하는aminohydrazide 2를 합성한 후에, 화합물 2를carbon disulfide와 반응시켜서 1,3,4-oxadiazole-5-thiol structure 3을 합성하였다. 얻어진 화합물 3을 either chloroacetone 또는 ethyl chloroacetate와 반응시켜서S-acyl 1,3,4-oxadiazole 유도체인 4 와 5를 합성하였으며, 또한 hydrazine hydrate와 반응시켜서 4-amino-1,2,4-triazole-5-thiol 유도체인 6을 합성하였으며, 화합물 6을 glacial acetic acid와 반응시켜서 6-methyl-1,3,4-triazolo[3,4-b]-1,3,4-thiadiazole (7)을 합성하였다. 한편, 알려진 방법에 따라서, 화합물 1로부터 tetrazolo[5,1-f]-1,2,4-triazine 9을 얻은 다음에, 화합물 9를 carbon disulfide와 반응시켜서 8-thione 유도체인 10을 합성한 후에, 대응하는 화합물 11, 12 및 13을 합성하였다. 얻어진 화합물13을 이용하여1,2,4-triazolo[4,3-d]tetrazolo[5,1-f]-1,2,4-triazines 14와 15를 합성하였다. 새롭게 합성한 화합물들의 화학구조를 확인하였으며, 합성한 화합물들에 대한 항균 활성시험을 수행하였다.

• 약학회지
• /
• 제37권2호
• /
• pp.113-118
• /
• 1993

3-Phenyl-5, 6, 7, 8-tetrahydrothiazolo[3, 2-$\alpha$][1, 3]diazepine, which has pharmaceutical activities, was reacted with phenyl isothiocyanate to give 3-phenyl-9-phenyl(thiocarbamoyl)-5, 6, 7, 8-tetrahydrothiazolo[3, 2-$\alpha$][1, 3]diazepi nium-betaine. New biheterocyclic compounds were prepared by the ring transformation reaction of the above reactive betaine with $\alpha$-haloesters and $\alpha$-haloketones such as ethyl bromoacetate, methyl bromoacetate, chloroacetone, and 4'-methoxyphenacyl bromide, respectively. In each ring transformation reaction, two major products supposed to be geometrical isomers were obtained.

• Archives of Pharmacal Research
• /
• 제19권3호
• /
• pp.235-239
• /
• 1996

Six, heretofore undescribed, $5^I-Methyl-5^I-(5-Substituted uracil-1-ylmethyl)-2^I-oxo-3^I-methylenetetrahydrofurans(F, Cl, Br, l, CH_3, H)(6a-f)$were synthesized and evaluated against three cell lines (FM-3A, P-388 and U-937). For the preparation of .alpha.-methylene-.gamma.-butyrolactone bearing 5-substituted uracils (6a-f), the effcient Reformatsky type reaction was employed which involves the treatment of ethyl .alpha.(bromomethyl) acrylate and zinc with the respective 5-substituted uracil-1-ylacetones (5a-f). The acetone derivatives (5a-f) were directly obtained by the respective alkylation reaction of 5-substituted uracils with chloroacetone in the presence of $K_{2}$$CO_{3}$(or NaH). These lactone compounds 6a-f exhibited moderate to significant activity in all of the three cell lines, and 6b, 6c and 6e showed significant antitumor activities (inhibitory concentrations ($IC_{50}$) ranged from 1.3-3.8 .mu.g/ml.

• Archives of Pharmacal Research
• /
• 제21권4호
• /
• pp.458-464
• /
• 1998

Search for a new $\alpha$-methylene-$\gamma$-butyrolactone-bearing 6-substituted purine as a potental antitumor agent has led to synthesize seven, hitherto unreported, $5^1$-Methyl-$5^1$-[(6-substituted-9H-purin-9-yl)methyl]-$2^1$-oxo-$3^1$- methylenetetrahydrofurans (H, Cl, l, $CH_3$, $NH_2$, SH, >C=O) (6a-g). These include $5^1$-Methyl-$5^1$-[(9H-purin-9-yl)methyll-$2^1$-oxo-$3^1$ -methylenetetrahydrofurans (6a), $5^1$-Methyl-$5^1$-[(6-chloro-9H-purin-9-yl)methyl]-$2^1$-oxo-$3^1$-methylenetetrahydr ofurans (6b), $5^1$-Methyl-$5^1$-[(6-chloro-9H-purin-9-yl) methyl]-$2^1$-oxo-$3^1$-methylenetetrahydrofurans (6c), $5^1$-Methyl-$5^1$-[(6-methyl-9H-purin-9-yl) methyl]-$2^1$-oxo-$3^1$-methylenetetrahydrofurans (6d), $5^1$-Methyl-$5^1$-[(9H-adenin-9-yl)methyll-$2^1$-oxo-$3^1$-methylenetetrahydrofurans (6e), $5^1$-Methyl-$5^1$-[(6-mercapto-9H-purin-9-yl) methyl]-$2^1$-oxo-$3^1$-methylenetetrahydrofurans (6f) and $5^1$-Methyl-$5^1$-[(9H-hypoxanthin-9-yl)methyll-$2^1$-oxo-$3^1$-methylenetetrahydrof urans (6g) which were made by the Reformatsky-type reaction of ethyl $\alpha$-(bromomethyl) acrylate with the corresponding (6-substituted-9H-purin-9-yl)-2-propanone intermediates (5a-g). These ketone intermediates 5a-g, 1-(9H-purin-9-yl)-2-propanone (5a), 1-(6-chloro-9H-purin-9-yl)-2-propanone (5b), 1-(6-iodo-9H-purin-9-yi)-2-propanone (5c), 1-(6-methyl-9H-purin-9-yl)-2-propanone (5d), 1-(9H-adenin-9-yl)-2-propanone (Se), 1-(6-mercapto-9H-purin-9-yl)-2-propanone (5f), and 1-(9H-hypoxanthin-9-yl)-2-propanone (5g) were directly obtained by the alkylation of the 6-substituted purine bases with the chloroacetone in the presence of $K_2$$CO_3$ (or NaH) under DMF (or DMSO). The preliminary in vitro cytotoxcity assay for the synthetic .alpha.-methylene-y-butyro-lactone compounds (6a-g) were determined against three cell lines (PM-3A, P-388, and K-562) and showed the moderate antitumor activity ($IC_50$ ranged from 1.4 to 4.3 $\mu\textrm{g}$/ml) with the compound $5^1$-methyl-$5^1$ -[(9H-hypoxanthin-9-yl)methyl]-$2^1$-oxo-$3^1$-methylenetetrahydrofuran (6g) showing the least antitumor activity.